HDAC9 and chronic myelogenous leukemia, BCR-ABL1 positive: The combination of an inhibitor of HDAC and 17-AAG is highly active in vitro against cells from chronic myeloid leukemia in blast crisis and AML cells harboring a FLT-3 mutation [41].